- Home
- FHN vs ROIV Comparison
FHN vs ROIV Comparison
Compare FHN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- ROIV
- Stock Information
- Founded
- FHN 1864
- ROIV 2014
- Country
- FHN United States
- ROIV United Kingdom
- Employees
- FHN N/A
- ROIV N/A
- Industry
- FHN Major Banks
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- FHN Finance
- ROIV Health Care
- Exchange
- FHN Nasdaq
- ROIV Nasdaq
- Market Cap
- FHN 10.7B
- ROIV 7.8B
- IPO Year
- FHN N/A
- ROIV N/A
- Fundamental
- Price
- FHN $21.92
- ROIV $11.40
- Analyst Decision
- FHN Buy
- ROIV Buy
- Analyst Count
- FHN 17
- ROIV 4
- Target Price
- FHN $23.09
- ROIV $17.50
- AVG Volume (30 Days)
- FHN 5.9M
- ROIV 7.9M
- Earning Date
- FHN 07-16-2025
- ROIV 08-07-2025
- Dividend Yield
- FHN 2.74%
- ROIV N/A
- EPS Growth
- FHN N/A
- ROIV N/A
- EPS
- FHN 1.44
- ROIV N/A
- Revenue
- FHN $3,043,000,000.00
- ROIV $29,053,000.00
- Revenue This Year
- FHN $11.18
- ROIV $3.28
- Revenue Next Year
- FHN $3.73
- ROIV $156.84
- P/E Ratio
- FHN $15.23
- ROIV N/A
- Revenue Growth
- FHN 3.43
- ROIV N/A
- 52 Week Low
- FHN $14.34
- ROIV $8.73
- 52 Week High
- FHN $22.44
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- FHN 68.56
- ROIV 54.55
- Support Level
- FHN $21.67
- ROIV $10.71
- Resistance Level
- FHN $22.22
- ROIV $11.58
- Average True Range (ATR)
- FHN 0.39
- ROIV 0.29
- MACD
- FHN 0.09
- ROIV 0.00
- Stochastic Oscillator
- FHN 87.94
- ROIV 62.16
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.